Corpus overview


MeSH Disease

Human Phenotype

Hypertension (443)

Fever (98)

Cough (85)

Pneumonia (79)

Obesity (73)


    displaying 201 - 210 records in total 443
    records per page

    COVID-19 infections MESHD and outcomes in patients with multiple myeloma HP multiple myeloma MESHD in New York City: a cohort study from five academic centers

    Authors: Malin Hultcrantz; Joshua Richter; Cara Rosenbaum; Dhwani Patel; Eric Smith; Neha Korde; Sydney Lu; Sham Mailankody; Urvi Shah; Alexander Lesokhin; Hani Hassoun; Carlyn Tan; Francesco Maura; Andriy Derkach; Benjamin Diamond; Adriana Rossi; Roger N Pearse; Deppu Madduri; Ajai Chari; David Kaminetzky; Marc Braunstein; Christian Gordillo; Faith Davies; Sundar Jagannath; Ruben Niesvizky; Suzanne Lentzsch; Gareth Morgan; Ola Landgren

    doi:10.1101/2020.06.09.20126516 Date: 2020-06-11 Source: medRxiv

    Importance: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma HP multiple myeloma MESHD have a compromised immune system, due to both the disease and anti- myeloma MESHD therapies, and may therefore be particularly susceptible to coronavirus disease MESHD 2019 (COVID-19); however, there is limited information to guide clinical management. Objective: To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma HP multiple myeloma MESHD. Design: Case-series. Setting: Five large academic centers in New York City. Participants: Patients with multiple myeloma HP multiple myeloma MESHD and related plasma SERO cell disorders who were diagnosed with COVID-19 between March 10th, 2020 and April 30th, 2020. Exposures: Clinical features and risk factors were analyzed in relation to severity of COVID-19. Main Outcomes and Measures: Descriptive statistics as well as logistic regression were used to estimate disease severity reflected in hospital admissions, intensive care unit (ICU) admission, need for mechanical ventilation, or death MESHD. Results: Of 100 multiple myeloma HP multiple myeloma MESHD patients ( male TRANS 58%; median age TRANS 68, range 41-91) diagnosed with COVID-19, 74 (74%) were admitted; of these 13 (18%) patients were placed on mechanical ventilation, and 18 patients (24%) expired. None of the studied risk factors were significantly associated (P>0.05) with adverse outcomes (ICU-admission, mechanical ventilation, or death MESHD): hypertension HP hypertension MESHD (N=56) odds ratio (OR) 2.3 (95% confidence interval [CI] 0.9-5.9); diabetes MESHD (N=18) OR 1.1 (95% CI 0.3-3.2); age TRANS >65 years (N=63) OR 2.0 (95% CI 0.8-5.3); high dose melphalan with autologous stem cell transplant <12 months (N=7) OR 1.2 (95% CI 0.2-7.4), IgG<650 mg/dL (N=42) OR=1.2 (95% CI 0.4-3.1). In the entire series of 127 patients with plasma SERO cell disorders, hypertension HP hypertension MESHD was significantly associated with the combined end-point (OR 3.4, 95% CI 1.5-8.1). Conclusions and Relevance: Although multiple myeloma HP myeloma MESHD patients have a compromised immune system due to both the disease and therapy; in this largest disease specific cohort to date of patients with multiple myeloma HP multiple myeloma MESHD and COVID-19, compared to the general population, we found risk factors for adverse outcome to be shared and mortality rates to be within the higher range of officially reported mortality rates.

    Possible COVID-19 recurrence in an older patient: a case report

    Authors: Antoine Garnier-Crussard; Marine Haution; Mathilde Gueret-Du-Manoir; Quitterie Reynaud; Nathalie Freymond; Maude Bouscambert-Duchamp; Anne Conrad; Claire Falandry

    doi:10.21203/ Date: 2020-06-11 Source: ResearchSquare

    Background: Novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-CoV-2) threatens the world for few months. Few cases of prolonged positivity of viral tests and clinical recurrence of COVID-19 have been described. We report the case of a 78-year-old woman with metastatic breast cancer MESHD who developed possible COVID-19 recurrence in a post-acute and rehabilitation unit. Case presentation: A 78-year-old woman with metastatic breast cancer MESHD and hypertension HP hypertension MESHD developed COVID-19. After symptom improvement and RT-PCR negativation, she regained symptom ( fever HP fever MESHD, fall HP) and lymphopenia HP lymphopenia MESHD on Day 26 and we note a turned positive RT-PCR even though she was tested positive for antibody SERO against SARS-CoV-2. After the diagnosis of possible COVID-19 recurrence, she was transferred back to an acute “COVID-19” unit and she then quickly clinically recovered. Conclusions: This clinical case allows us to discuss the risk of recurrence and possible specific causes in older patients. Moreover, prolonged symptoms and lymphopenia HP lymphopenia MESHD could be associated to worse outcomes in older patients. Finally, at a collective level, even if traces TRANS of virus detected by RT-PCR were not necessarily correlated with the contagiousness, the importance of possible COVID-19 recurrence in the care pathway for older adults TRANS must be taken into account, since they are often surrounded by frail older people.

    Assessment of Experiences of Preventive Measures Practice including Vaccination History and Health Education among Umrah Pilgrims in Saudi Arabia, 1440H-2019

    Authors: Mansour Tobaiqy; Sami S Almudarra; Manal M Shams; Samar A Amer; Mohamed F Alcattan; Ahmed H Alhasan

    doi:10.1101/2020.06.09.20126581 Date: 2020-06-11 Source: medRxiv

    Background Annually, approximately 10 million Umrah pilgrims travel TRANS to the Kingdom of Saudi Arabia for Umrah from more than 180 countries. This event presents major challenges for the Kingdom public health sector, which strives to decrease the burden of infectious diseases MESHD and to adequately control its spread. Aims of the study The aims of the study were to assess the experiences of preventive measures practice, including vaccination history and health education, among Umrah pilgrims in Saudi Arabia. Methods A cross sectional survey administered to a randomly selected group of pilgrims by the research team members from February to the end of April 2019 at the departure lounge at King Abdul Aziz International airport, Jeddah city. The questionnaire was comprised of questions on the following factors: sociodemographic information, level of education, history of vaccinations and chronic illnesses, whether the pilgrim has received any health education and orientation prior to coming Saudi Arabia or on their arrival, and their experiences with preventive medicine. Results Pilgrims (n=1012) of 48 nationalities completed the survey and were reported in this study. Chronic diseases MESHD (n=230) were reported among pilgrims, with hypertension HP hypertension MESHD being the most reported morbidity (n=124, 53.9%). The majority of pilgrims had taken immunization prior to travel TRANS to Saudi Arabia, and the most commonly reported immunizations were meningitis HP meningitis MESHD (n=567, 56%), influenza (n=460, 45.5%), and Hepatitis HP Hepatitis MESHD B virus vaccinations (n=324, 32%); however, 223(22%) had not received any vaccinations prior to travel TRANS, including meningitis HP meningitis MESHD vaccine, which is mandatory in Saudi Arabia. 305 pilgrims (30.1%) had reported never using face masks in crowded areas; however, 63.2% reported lack of availability of these masks. The majority of participants had received health education on preventive measures, including hygienic aspects (n=799, 78.9%) mostly in their home countries (n=450, 56.3%). A positive association was found between receiving health education and practicing of preventive measures, such as wearing masks in crowded areas (P= 0.04) and other health practice scores (P= 0.02). Conclusion Although the experiences of the preventive measures among pilgrims in terms of health education, vaccinations, and hygienic practices were overall positive, this study identified several issues with the following preventive measures: immunizations particularly meningitis HP meningitis MESHD vaccine and using face masks in crowded areas. Further studies are required to develop a health education module to promote comprehensive preventive measures for pilgrims. Keywords Umrah, pilgrims, personal preventive measures, COVID-19, Makkah, Saudi Arabia

    Level of the SARS-CoV-2 receptor ACE2 is highly elevated in old- aged TRANS patients with aortic stenosis MESHD: implications for ACE2 as a biomarker for the severity of COVID-19

    Authors: Miklós Fagyas; Attila Kertész; Ivetta Siket Mányiné; Viktor Bánhegyi; Bertalan Kracskó; Andrea Szegedi; Miklós Szokol; Gusztáv Vajda; Ildikó Rácz; Zoltán Csanádi; Zoltán Papp; Attila Tóth; Sándor Sipka

    doi:10.21203/ Date: 2020-06-10 Source: ResearchSquare

    Coronavirus disease MESHD 2019 (COVID-19) has a high mortality in elderly TRANS patients with pre- existing cardiovascular diseases MESHD. The cellular receptor of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is the angiotensin converting enzyme 2 (ACE2), thereby implicating a link between cardiovascular diseases MESHD and SARS-CoV-2 susceptibility. Aortic stenosis MESHD ( AS MESHD) represents a chronic inflammatory state with severe cardiovascular complications MESHD in the elderly TRANS, a prime condition for COVID-19 mortality. The circulating ACE2 levels were measured in 111 patients with severe AS MESHD and compared to patients with hypertension HP hypertension MESHD and healthy individuals.About 4-times higher circulating ACE2 activity was found in patients with severe AS MESHD than in hypertensives MESHD or healthy individuals (103.4±5.4, n=111, 24.4±0.6, n=540 and 17.3±1.3±0.6 mU/L, n=46, respectively). Patients with severe AS MESHD were older than patients with hypertension HP hypertension MESHD (79±0.7 years vs. 60±0.5 years, P<0.05). Serum SERO ACE2 activity correlated negatively with the left ventricular ejection fraction and positively with the right ventricular systolic pressure in patients with AS MESHD. In contrast, circulating ACE2 activity was independent of the blood SERO pressure, characteristics of the stenotic aortic valve (aortic valve area, peak flow velocity), kidney function (GFR) and inflammatory state (CRP). We found no effect of RAAS inhibitory drugs on the serum SERO ACE2 activity in this group of patients.Our results illustrate circulating ACE2 as a potential interface between chronic inflammation MESHD, cardiovascular disease MESHD and COVID-19 susceptibility. Elderly TRANS patients with AS MESHD have markedly elevated ACE2 levels together with altered left and right ventricular functions, which may pose higher risks during COVID-19. Our clinical data do not support a role for RAAS inhibitors in regulating circulating ACE2 levels.

    Bipallidal Lesions MESHD in a COVID-19 Patient: A Case Report and Brief Review of Literature

    Authors: Sudhat Ashok; Kalyan Shastri; L. Beryl Guterman; Lee R. Guterman

    doi:10.21203/ Date: 2020-06-09 Source: ResearchSquare

    BackgroundAltered mentation in COVID-19 patients can be a function of any number of metabolic abnormalities MESHD associated with the infection MESHD. Here we present the case of an encephalopathic COVID-19 patient with bilateral globus pallidus lesions. While imaging abnormalities involving basal ganglia MESHD have been reported in encephalitis HP encephalitis MESHD caused by neuroinvasive flaviviruses, the bipallidal lesions noted here likely resulted from hypoxic-ischemic brain injury MESHD.Case PresentationA 51-year-old African American woman was found unresponsive at home by her fiancé. She had been complaining of shortness of breath MESHD and cough HP for three days. She is a former smoker with past medical history of hypertension HP hypertension MESHD, nephropathy HP nephropathy MESHD, and bipolar disorder MESHD. Upon examination, she was alert but nonverbal, following commands inconsistently, and unable to move extremities against gravity. After several minutes, she was able to state her name but kept repeating it in response to all questions. Chest radiograph revealed bilateral lung infiltrates. CT of the head showed hypodensities in bilateral globus pallidi. A non-contrast MRI of the brain showed symmetric restricted diffusion and FLAIR hyperintense signal changes in bilateral globus pallidi. Abnormal SWI signal seen in bilateral globus pallidi likely represents mineralization or hemosiderin. There were no striatal or thalamic lesions. Major intracranial arteries were widely patent.The patient later tested positive for 2019-nCoV using real-time PCR assay, and was transferred to our COVID-19 designated hospital campus. Thereafter, she had waxing and waning mentation. Repeat CT imaging 11 days after the first scan demonstrated resolution of the bipallidal hypodensities. The patient was recently discharged to a subacute rehab facility but is still experiencing confusion HP confusion MESHD.ConclusionsAs we come across neurological manifestations of COVID-19, we believe neuroimaging is likely to play an important role in establishing if central nervous system involvement is invariably due to indirect mechanisms such as metabolic or hypoxic-ischemic brain injury MESHD or if direct neuroinvasive disease MESHD is a possibility, as with certain viruses.

    Mortality Analysis of COVID-19 Confirmed cases TRANS in Pakistan

    Authors: Ambreen Chaudhry; Aamer Ikram; Mirza Amir Baig; Muhammad Salman; Tamkeen Ghafoor; Zakir Hussain; Mumtaz Ali Khan; Jamil Ahmad Ansari; Asif Syed; Wasif Javed; Ehsan Larik; Muhammad Mohsan Wattoo; Naveed Masood; zeeshan Iqbal Baig; Khurram Akram

    doi:10.1101/2020.06.07.20121939 Date: 2020-06-09 Source: medRxiv

    Introduction: COVID-19, a novel disease, appeared in December 2019 in China and rapidly spread across the world. Till the second week of April 2020, high incidence (2.9/100,000) and cases fatality rates (1.7%) were observed in Pakistan. This study was conducted to determine the temporal and spatial distribution of the first 100 deaths attributed to COVID-19 in Pakistan and their associated demographic factors. Method: We conducted a descriptive epidemiological analysis of the first 100 deaths MESHD reported among RT-PCR confirmed COVID-19 cases. Demographic, epidemiological, and risk factors information was obtained associated comorbidities and clinical signs and symptoms were recorded and frequencies were determined. Results: A total of 100 mortalities with overall Case Fatality Rate 1.67% (CFR) were analysed. Median age TRANS of patients was 64.5 years (IQR: 54-70) with 75% (n=75) Males TRANS. Among all deaths MESHD reported, 71 (71%) cases had one or more documented comorbidities at the time of diagnosis. Most frequently reported co-morbidities were; hypertension HP hypertension MESHD (67 %), followed by Diabetes Mellitus HP Diabetes Mellitus MESHD 945%) and Ischemic Heart Diseases MESHD (27%). First death MESHD was reported on 18 March 2020 and the most frequent presenting symptoms were shortness of breath MESHD (87%) and fever HP fever MESHD (79%). Median duration of illness was eight days (IQR: 4-11 days), the median delay reaching hospital to seek health care was three days (IQR: 0-6 days) while median duration of hospital stay was also three days (IQR: 1-7 days). Among all reported deaths MESHD, 62% were attributed to local transmission TRANS as these cases had no history of international travel TRANS. The most affected age group TRANS was 60-69 years while no death reported in age group TRANS below 20 years. Conclusion: High CFR among old age group TRANS and its association with co-morbidities (chronic disease) suggests targeted interventions such as social distancing and strict quarantine measure for elderly TRANS and morbid people. Comparative studies among deaths MESHD and recovered patients are recommended to explore further disease dynamics. Key words: COVID-19, Cases Fatality Rates, Co-morbidities, Epidemiology, Pakistan, Co-morbidities

    Analysis of the effect of proton pump inhibitors on the course of common COVID-19

    Authors: Xiao-Yu Zhang; Hai-Bing Wu; Yun Ling; Zhi-Ping Qian; Liang Chen

    doi:10.1101/2020.06.07.20124776 Date: 2020-06-09 Source: medRxiv

    Background/aims: To evaluate the effect of proton pump inhibitors on the course of common COVID-19. Methods: Clinical data of common COVID-19 patients admitted to the Shanghai public health clinical center for treatment from January 20, 2020 to March 16, 2020 were collected. A retrospective study was conducted and the patients were divided into two groups according to whether they used proton pump inhibitors or not. The differences in SARS-CoV-2 clearance and hospital stay between the two groups were compared by univariate and multivariate analyses. Results: A total of 154 COVID-19 common cases were included in this study, including 80 males TRANS (51.9%), 35 patients (22.7%) in the proton pump inhibitors group, and 119 patients (77.3%) in the control group. In the proton pump inhibitors group and the control group, the duration of SARS-CoV-2 clearance were 7(6-9) and 7(6-11) days, and the duration of hospital stay was 21(16-25) and 20(15-26) days, respectively. There was no significant difference between the two groups in the cumulative incidence of SARS-CoV-2 clearance and the cumulative incidence of discharge, and the same after Propensity Score Match, all P > 0.05. Multivariate analysis suggested that chronic gastropathy prolonged MESHD the duration of SARS-CoV-2 clearance, the HR was 20.924(3.547-123.447). Hypertension HP Hypertension MESHD, chronic obstructive pulmonary disease HP obstructive pulmonary disease MESHD, chronic liver disease MESHD and malignant tumor MESHD all increased the duration of hospital stay for COVID-19, and the HR were 1.820 (1.073-3.085), 4.370 (1.205-15.844), 9.011 (2.681-30.290) and 5.270 (1.237-22.456), respectively; the duration of hospital stay in COVID-19 patients was shortened by SARS-CoV-2 clearance, and the HR was 0.907 (0.869-0.947); all P < 0.05. Conclusion: Proton pump inhibitors use have no effect on the prolonging or shortening of the course of adults TRANS hospitalized with COVID-19.

    The hypothalamus MESHD as a hub for putative SARS-CoV-2 brain infection MESHD

    Authors: Sreekala Nampoothiri; Florent Sauve; Gaetan Ternier; Daniela Fernandois; Caio Coelho; Monica Imbernon; Eleonora Deligia; Romain Perbet; Vincent Florent; Marc Baroncini; Florence Pasquier; Francois Trottein; Claude-Alain Maurage; Virginie Mattot; Paolo Giacobini; S. Rasika; Vincent Prevot

    doi:10.1101/2020.06.08.139329 Date: 2020-06-09 Source: bioRxiv

    Most patients with COVID-19, caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), display neurological symptoms MESHD, and respiratory failure HP respiratory failure MESHD in certain cases could be of extra-pulmonary origin. Hypothalamic neural MESHD circuits play key roles in sex differences, diabetes MESHD, hypertension HP hypertension MESHD, obesity HP obesity MESHD and aging, all risk factors for severe COVID-19, besides being connected to olfactory/gustative and brainstem cardiorespiratory centers. Here, human brain gene-expression analyses and immunohistochemistry reveal that the hypothalamus MESHD and associated regions express angiotensin-converting enzyme 2 and transmembrane proteinase, serine 2, which mediate SARS-CoV-2 cellular entry, in correlation with genes or pathways involved in physiological functions or viral pathogenesis. A post-mortem patient brain shows viral invasion and replication in both the olfactory bulb and the hypothalamus MESHD, while animal studies indicate that sex hormones and metabolic diseases influence this susceptibility.

    Extremely severe case of COVID-19 pneumonia HP pneumonia MESHD recovered despite bad prognostic indicators: a didactic report

    Authors: Enrico Bentivegna; M. Luciani; V Spuntarelli; M L Speranza; L Guerritore; A Sentimentale; P Martelletti

    doi:10.21203/ Date: 2020-06-08 Source: ResearchSquare

    Introduction: COVID-19 is a highly infectious respiratory disease MESHD caused by Severe Acute Respiratory Syndrome MESHD - Coronavirus - 2 (SARS-COV2). Starting from Wuhan (China) where it was firstly reported, it rapidly spread to the rest of the world, causing a pandemic with more than 300.000 deaths to date. Case presentation: we report an extremely severe case of coronavirus pneumonia MESHD pneumonia HP in an over-80 years old patient with hypertension HP hypertension MESHD, coronary heart disease MESHD, chronic heart failure MESHD and chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD. Despite several bad anamnestic indicators, the severe clinical conditions and complications that arose during hospitalization, the patient recovered and was discharged.Conclusions: Although a higher vulnerability of geriatric patients has been observed, the literature on elderly TRANS COVID-19 patients have remained very scarce, especially in those over 80. The aim of this paper is to describe an extremely severe case of coronavirus pneumonia MESHD pneumonia HP in an over-80 years old patient that, despite a clearly poor anamnestic and clinical prognostic forecast was successfully discharged thanks to a careful evaluation of the case and of the complications that have arisen. Several efforts have been made to identify therapeutic strategies and prognostic indicators of COVID-19 but there is still much to learn. With this report, we hope to provide important elements to better understand this disease.

    Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis

    Authors: Carlos Diaz-Arocutipa; Jose Saucedo-Chinchay; Adrian V. Hernandez

    doi:10.1101/2020.06.03.20120261 Date: 2020-06-08 Source: medRxiv

    Importance: There is a controversy regarding whether or not to continue angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19). Objective: To evaluate the association between ACEIs or ARBs use and clinical outcomes in COVID-19 patients. Data Sources: Systematic search of the PubMed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials from database inception to May 31, 2020. We also searched the preprint servers medRxiv and SSNR for additional studies. Study Selection: Observational studies and randomized controlled trials reporting the effect of ACEIs or ARBs use on clinical outcomes of adult TRANS patients with COVID-19. Data Extraction and Synthesis: Risk of bias of observational studies were evaluated using the Newcastle-Ottawa Scale. Meta-analyses were performed using a random-effects models and effects expressed as Odds ratios (OR) and mean differences with their 95% confidence interval (95%CI). If available, adjusted effects were pooled. Main Outcomes and Measures: The primary outcome was all-cause mortality and secondary outcomes were COVID-19 severity, hospital discharge, hospitalization, intensive care unit admission, mechanical ventilation, length of hospital stay, and troponin, creatinine, procalcitonin, C-reactive protein (CRP), interleukin-6 (IL-6), and D-dimer levels. Results: 40 studies (21 cross-sectional, two case-control, and 17 cohorts) involving 50615 patients were included. ACEIs or ARBs use was not associated with all-cause mortality overall (OR 1.11, 95%CI 0.77-1.60, p=0.56), in subgroups by study design and using adjusted effects. ACEI or ARB use was independently associated with lower COVID-19 severity (aOR 0.56, 95%CI 0.37-0.87, p<0.01). No significant associations were found between ACEIs or ARBs use and hospital discharge, hospitalization, mechanical ventilation, length of hospital stay, and biomarkers. Conclusions and Relevance: ACEIs or ARBs use was not associated with higher all-cause mortality in COVID-19. However, ACEI or ARB use was independently associated with lower COVID-19 severity. Our results support the current international guidelines to continue the use of ACEIs and ARBs in COVID-19 patients with hypertension HP.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.